Genmab chief on sclerosis drug launch: Novartis prioritizes us
While Genmab's partner Novartis can start launching sclerosis drug Kesimpta in Europe after receiving EU authorization, the process is well underway in the US – and it's going well, according to CEO Jan van de Winkel.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
On Tuesday, the EU Commission approved the drug Kesimpta, which was developed by Genmab, as a treatment for sclerosis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
